Tell me about overin cyst. Size and treatment in detail, research base

Reading File

Finding Sources

Searching PubMed

"ovarian cyst" AND management

Searching the Web

ovarian cyst size treatment guidelines when to remove surgery

Finding Sources

Reading File

Searching Images

ovarian cyst ultrasound simple complex

This diagnostic image consists of two side-by-side transvaginal ultrasound views of the pelvic region. The left panel shows the 'Rt Adnexa' with a heterogeneous, mixed echogenicity appearance, suggesting complex pathology such as a tubo-ovarian complex or hydrosalpinx. The right panel displays the 'Rt Ovary' using Color Doppler imaging, highlighting a large, unilocular, simple cyst. The cyst is characterized by its uniformly anechoic (black) internal fluid, well-defined smooth walls, and thin peripheral vascularization indicated by the red and blue Doppler signals. The comparison illustrates the visual difference between a simple ovarian cyst and complex adnexal structures. This material is suitable for medical education in obstetrics and gynecology, specifically for teaching sonographic identification of pelvic masses, ovarian cysts, and adnexal inflammation.

This diagnostic image consists of two side-by-side transvaginal ultrasound frames demonstrating ovarian pathology in a 27-year-old female. The left panel shows a simple ovarian cyst (indicated by a yellow arrow). It is characterized by a well-defined, thin-walled, anechoic (black) fluid-filled sac with acoustic enhancement posteriorly, representing a classic simple cyst morphology. The right panel demonstrates a complex ovarian cyst (indicated by a red arrow). This structure is characterized by a heterogeneous and disorganized internal architecture, containing low-level internal echoes and thickened, irregular borders, which contrast with the clear fluid of the simple cyst. Both images include linear measurement callouts in the bottom-right corners (e.g., D1, D2) for volumetric assessment. These findings are clinically significant in the differential diagnosis of adnexal masses, particularly in cases of suspected ectopic pregnancy or hemorrhagic cysts, where distinguishing between simple fluid and complex internal debris is critical for determining management pathways.

This diagnostic image is a transabdominal pelvic ultrasound demonstrating bilateral ovarian enlargement due to multicystic masses, specifically focused on the left ovary. Two distinct cystic structures are identified and labeled. Cyst A is a smaller, well-defined, simple anechoic cyst with smooth, thin borders and no internal septations or solid components. Cyst B is significantly larger, predominantly anechoic with some irregular internal echoes or artifacts, and appears less circumscribed than Cyst A. Anatomical landmarks labeled include the 'Left Ovary' and the 'Urinary Bladder' situated at the periphery. The ultrasound findings are consistent with ovarian hyperstimulation or multicystic ovaries, demonstrating significant volume increase in the adnexal structures. This visual is intended for educational use in obstetrics and gynecology to illustrate sonographic characteristics of simple versus complex ovarian cysts and pelvic anatomy under pathological conditions.

This diagnostic image consists of two side-by-side transvaginal pelvic ultrasound views of the right adnexa. The scan reveals a unilocular simple cyst within the right ovary. Visually, the cyst is characterized by a well-defined, thin, smooth wall and a purely anechoic (black) internal lumen, signifying clear fluid content without internal septations, papillary projections, or solid mural components. Acoustic enhancement is visible deep to the cyst, a typical finding for fluid-filled structures. The surrounding ovarian stroma and adjacent pelvic soft tissues exhibit heterogeneous, intermediate echogenicity. Measurement markers on the second frame assist in determining the volume and dimensions of the cyst. This image serves as a clinical example of a benign-appearing ovarian cyst, used in gynecological education to differentiate simple cysts from complex tubo-ovarian masses or hydrosalpinx.

This diagnostic image is a transvaginal ultrasound scan of the female pelvis focusing on the right adnexa. It demonstrates a right ovarian cyst, approximately 3.5 cm in size, highlighted by multiple white arrows. The lesion presents as a complex cystic structure with mixed echogenicity. Key visual features include well-defined but irregular borders and a heterogeneous internal composition characterized by low-level internal echoes and thin, stringy internal septations. These fine, hyperechoic strands cross the primarily hypoechoic fluid-filled space, creating a multi-loculated appearance typical of complex cysts. In the provided clinical context, these findings are consistent with an evolving ovarian dermoid cyst (mature cystic teratoma) or a hemorrhagic cyst. The image serves as an educational example of pelvic sonography used to differentiate simple fluid-filled follicles from complex adnexal masses based on internal architecture and echotexture.

Reading File

Reading Article

PMID: 36787526

Ovarian Cysts: Size Criteria and Treatment

What it is

An ovarian cyst is a fluid-filled (or fluid-and-solid) sac that forms in or on the ovary. Most are functional cysts (follicular or corpus luteum cysts) that arise from the normal menstrual cycle and resolve on their own. Others are pathological: endometriomas ("chocolate cysts"), mature cystic teratomas (dermoid cysts), serous/mucinous cystadenomas, or (rarely) malignant neoplasms.

Simple vs complex ovarian cyst on ultrasound

Size thresholds guiding management

There is a widely used "1-2-3 rule" for adnexal structures on ultrasound:

< 1 cm: normal follicles
1-3 cm: dominant/functional follicles, physiological
> 3 cm: termed a "cyst," warrants characterization (wall thickness, septations, solid components, Doppler flow)

Beyond that, size-based decision points from Berek & Novak's Gynecology, Schwartz's Principles of Surgery, and current practice are:

Size / feature	Typical management
Simple, unilocular, thin-walled, < 5 cm, asymptomatic, normal CA-125	Reassurance; often no follow-up needed (very likely physiological)
Simple, unilocular, < 10 cm, normal CA-125 (any age)	Can be followed conservatively with serial ultrasound; malignancy risk is extremely low - Berek & Novak's Gynecology
Postmenopausal, predominantly cystic, up to 8 cm	May be observed or given a short course of oral contraceptives; repeat imaging in 2 menstrual cycles - Berek & Novak's Gynecology
Simple cyst > 4-5 cm	Generally considered for resection as spontaneous resolution is unlikely - Schwartz's Principles of Surgery
Persistent or symptomatic simple cyst 5-10 cm	Surgical evaluation favored, especially if symptomatic
Any complex cyst (septations, solid parts, papillary projections, ascites) regardless of size	Surgical evaluation warranted, work-up for malignancy
> 10 cm, or solid component, or abnormal Doppler/CA-125	Higher malignancy suspicion; surgical staging capability should be available
Up to ~20 cm	Can usually still be removed laparoscopically
> 20 cm	Often requires open laparotomy for safe removal

In pregnancy/fetal medicine, a fetal ovarian cyst ≥ 5 cm, or one growing ≥ 1 cm/week, is an indication to consider intrauterine aspiration to reduce the risk of torsion and later oophorectomy (postpartum oophorectomy rate drops from 85% to 14% with aspiration) - Creasy & Resnik's Maternal-Fetal Medicine.

Treatment approach by scenario

1. Reproductive-age women, simple cyst

< 5-8 cm, asymptomatic: expectant management, repeat transvaginal ultrasound in 6-8 weeks (many are corpus luteum cysts that resolve within 1-3 cycles). Oral contraceptives do not shrink existing cysts but can reduce new functional cyst formation.
Persistent, enlarging, symptomatic, or > 5-10 cm: laparoscopic cystectomy (ovary-sparing) preferred over oophorectomy when fertility is a priority.

2. Postmenopausal women

Simple, unilocular cysts up to 8-10 cm with normal CA-125: can be safely observed. A 2023 systematic review/meta-analysis of 1,672 postmenopausal women found simple cysts resolved spontaneously in ~34% and remained stable in ~39%; only ~19% went to surgery (usually by patient preference), and the malignancy rate was about 1 in 10,000 (PMID: 36787526). This supports conservative management for truly simple cysts even after menopause.
Complex morphology, elevated CA-125, solid components, or rapid growth: warrants gynecologic oncology referral and surgical excision (usually oophorectomy given lower fertility priority and higher cancer suspicion in this group).

3. Endometriomas

Symptomatic or those affecting fertility are typically managed surgically (cystectomy). Medical therapy (GnRH agonists, danazol, progestins, aromatase inhibitors) can suppress growth/symptoms but does not eliminate the cyst - a 2024 meta-analysis found medical therapy reduces cyst size and pain but recurrence is common after stopping treatment (PMID: 37944155).
Caution: laparoscopic electrocoagulation of the cyst bed to control bleeding after endometrioma cystectomy is associated with measurable damage to ovarian reserve (lower AMH) compared with suturing - a 2024 systematic review/meta-analysis (PMID: 39145875).

4. Neonatal/fetal simple ovarian cysts

Most regress spontaneously. A 2024 European Paediatric Surgeons' Association consensus statement recommends observation for simple cysts, with intervention (aspiration or laparoscopic surgery) reserved for large (typically > 4-5 cm), symptomatic, or complex/torsed cysts to preserve ovarian tissue (PMID: 37557903).

5. Acute complications (torsion, rupture, hemorrhage)

Larger cysts (generally > 5 cm) carry higher torsion risk. Acute severe pain, peritoneal signs, or hemodynamic instability from rupture/hemorrhage requires urgent surgical evaluation, sometimes emergent laparoscopy.
Intraoperative cyst spillage (e.g., dermoid, endometrioma) during cystectomy has a well-documented but generally low risk of chemical peritonitis or local recurrence, per a 2021 systematic review/meta-analysis (PMID: 33279627); careful surgical technique to avoid spillage is still recommended.

Surgical options

Cystectomy (ovary-sparing removal of the cyst wall): preferred when fertility preservation matters and the cyst appears benign.
Oophorectomy: considered for postmenopausal women, very large cysts, or when malignancy is suspected.
Laparoscopy: first-line for most benign-appearing cysts, feasible for masses up to ~15-20 cm depending on surgeon experience and cyst characteristics.
Laparotomy: reserved for very large cysts, suspected malignancy needing full staging, or when laparoscopic removal isn't safe.

Bottom line

Size alone rarely dictates treatment in isolation - morphology (simple vs complex), symptoms, menopausal status, CA-125, and growth pattern matter as much as absolute size. A reasonable rule of thumb: simple cysts under 5 cm are usually observed, 5-10 cm warrant closer surveillance or consideration of surgery depending on symptoms/persistence, and anything over 10 cm or with complex/solid features generally merits surgical evaluation.

No recent meta-analyses or guidelines were found that contradict these thresholds; the 2023 postmenopausal cyst meta-analysis (PMID: 36787526) and the 2024 neonatal consensus statement (PMID: 37557903) both reinforce a trend toward more conservative management of simple cysts across age groups when malignancy risk is low.

35 mm in size unilateral adrenal

Finding Sources

Searching PubMed

"adrenal incidentaloma" AND management

Searching the Web

adrenal incidentaloma 35mm size cutoff surgery guidelines

Reading File

Reading Article

PMID: 37318239

35 mm Unilateral Adrenal Mass (Adrenal Incidentaloma)

A 3.5 cm unilateral adrenal mass falls just under the most widely used "high-risk" size cutoff of 4 cm, so size alone does not mandate surgery here - but a full functional and imaging work-up is still required before deciding on observation vs. resection.

Step 1: Is it functional? (biochemical work-up - do this regardless of size)

Per Current Surgical Therapy and the 2023 European Society of Endocrinology (ESE) guideline (PMID: 37318239), every incidentaloma needs:

1 mg overnight dexamethasone suppression test (cortisol > 1.8 µg/dL [>50 nmol/L] suggests autonomous cortisol secretion - now termed "mild autonomous cortisol secretion," MACS)
Plasma or 24-hour urinary fractionated metanephrines (rule out pheochromocytoma)
Plasma aldosterone/renin ratio if hypertensive and/or hypokalemic (rule out primary aldosteronism)
Clinical screen for Cushingoid features, catecholamine excess symptoms (headache, palpitations, diaphoresis), and hypokalemia/refractory hypertension

If hormonally active (Cushing's, pheochromocytoma, aldosteronoma) -> surgery is indicated regardless of the 3.5 cm size.

Step 2: Malignancy risk by imaging + size

On unenhanced CT:

Homogeneous and ≤10 Hounsfield units (HU) -> classic benign adenoma appearance -> no further imaging needed, regardless of size (this is a key change in the 2023 ESE guideline)
If not clearly benign (HU >10, heterogeneous, irregular margins) -> needs further characterization (washout CT, MRI, or multidisciplinary discussion)

Size-stratified malignancy risk (adrenocortical carcinoma), from Current Surgical Therapy / Campbell-Walsh Urology:

Size	Approx. ACC risk	Typical recommendation
< 4 cm	~2-3%	Observation if benign imaging features and non-functional
4-6 cm	~6-7%	Consider adrenalectomy if surgically fit
> 6 cm	~25%	Adrenalectomy generally recommended

At 35 mm, the mass is in the low-risk (<4 cm) category for malignancy. Per the ESE/ENSAT 2023 guideline, surgery for a purely size-based indication is reserved for masses >4 cm that are also inhomogeneous or have HU >20 - a 3.5 cm lesion doesn't meet this threshold on size alone.

Step 3: Decision

Non-functional + clearly benign imaging (homogeneous, ≤10 HU): no surgery, no further imaging needed at all - this is a genuinely benign adenoma.
Non-functional + indeterminate imaging: multidisciplinary discussion; options are additional imaging (washout CT or MRI), interval follow-up imaging at 6-12 months, or (individualized) surgery. A significant interval growth (ESE: >20% and ≥5 mm; older AACE/AAES criteria: ≥0.5-1 cm) raises suspicion and favors resection.
Functional (even mild/subclinical cortisol excess with comorbidities like hypertension or type 2 diabetes): surgery should be considered on an individualized basis even without malignant features.
Suspicious features regardless of size (irregular margins, rapid growth, necrosis, calcification, local invasion): resection.

If surgery is chosen

At 35 mm, this is comfortably within the range for minimally invasive (laparoscopic) adrenalectomy - NCCN's cutoff for laparoscopic approach is up to 4 cm, while ESE/ENSAT extends it to 6 cm; open adrenalectomy is reserved for larger or overtly malignant-appearing tumors.

Bottom line for a 35 mm unilateral adrenal incidentaloma

Rule out hormone excess (cortisol, metanephrines, aldosterone/renin if hypertensive/hypokalemic).
Characterize on unenhanced CT: if homogeneous and ≤10 HU, this is a benign adenoma - no surgery, no further imaging.
If indeterminate imaging or any functionality, individualize between interval imaging (6-12 months) and laparoscopic adrenalectomy - size alone (3.5 cm) is not an automatic indication for surgery, since it's below the ~4-6 cm thresholds most guidelines use to trigger resection based on size.

Sources: Current Surgical Therapy, 14th ed. (Adrenal Incidentaloma chapter); Campbell-Walsh-Wein Urology (Adrenal Masses); the 2023 ESE/ENSAT clinical practice guideline on adrenal incidentalomas (PMID: 37318239); and the 2023 CUA/AUA-endorsed guideline on incidentally discovered adrenal masses (PMID: 37556768), which corroborates the same size/imaging-based risk stratification.

Fluid Field

I'm not sure what you mean by "Fluid Field" - could you clarify? A few possibilities:

Asking for Preferences

What are you asking about with 'Fluid Field'?

Ovarian Cysts: Size Criteria and Treatment

What it is

An ovarian cyst is a fluid-filled (or fluid-and-solid) sac that forms in or on the ovary. Most are functional cysts (follicular or corpus luteum cysts) that arise from the normal menstrual cycle and resolve on their own. Others are pathological: endometriomas ("chocolate cysts"), mature cystic teratomas (dermoid cysts), serous/mucinous cystadenomas, or (rarely) malignant neoplasms.

Size thresholds guiding management

There is a widely used "1-2-3 rule" for adnexal structures on ultrasound:

< 1 cm: normal follicles
1-3 cm: dominant/functional follicles, physiological
> 3 cm: termed a "cyst," warrants characterization (wall thickness, septations, solid components, Doppler flow)

Beyond that, size-based decision points from Berek & Novak's Gynecology, Schwartz's Principles of Surgery, and current practice are:

Size / feature	Typical management
Simple, unilocular, thin-walled, < 5 cm, asymptomatic, normal CA-125	Reassurance; often no follow-up needed (very likely physiological)
Simple, unilocular, < 10 cm, normal CA-125 (any age)	Can be followed conservatively with serial ultrasound; malignancy risk is extremely low - Berek & Novak's Gynecology
Postmenopausal, predominantly cystic, up to 8 cm	May be observed or given a short course of oral contraceptives; repeat imaging in 2 menstrual cycles - Berek & Novak's Gynecology
Simple cyst > 4-5 cm	Generally considered for resection as spontaneous resolution is unlikely - Schwartz's Principles of Surgery
Persistent or symptomatic simple cyst 5-10 cm	Surgical evaluation favored, especially if symptomatic
Any complex cyst (septations, solid parts, papillary projections, ascites) regardless of size	Surgical evaluation warranted, work-up for malignancy
> 10 cm, or solid component, or abnormal Doppler/CA-125	Higher malignancy suspicion; surgical staging capability should be available
Up to ~20 cm	Can usually still be removed laparoscopically
> 20 cm	Often requires open laparotomy for safe removal

In pregnancy/fetal medicine, a fetal ovarian cyst ≥ 5 cm, or one growing ≥ 1 cm/week, is an indication to consider intrauterine aspiration to reduce the risk of torsion and later oophorectomy (postpartum oophorectomy rate drops from 85% to 14% with aspiration) - Creasy & Resnik's Maternal-Fetal Medicine.

Treatment approach by scenario

1. Reproductive-age women, simple cyst

< 5-8 cm, asymptomatic: expectant management, repeat transvaginal ultrasound in 6-8 weeks (many are corpus luteum cysts that resolve within 1-3 cycles). Oral contraceptives do not shrink existing cysts but can reduce new functional cyst formation.
Persistent, enlarging, symptomatic, or > 5-10 cm: laparoscopic cystectomy (ovary-sparing) preferred over oophorectomy when fertility is a priority.

2. Postmenopausal women

Simple, unilocular cysts up to 8-10 cm with normal CA-125: can be safely observed. A 2023 systematic review/meta-analysis of 1,672 postmenopausal women found simple cysts resolved spontaneously in ~34% and remained stable in ~39%; only ~19% went to surgery (usually by patient preference), and the malignancy rate was about 1 in 10,000 (PMID: 36787526). This supports conservative management for truly simple cysts even after menopause.
Complex morphology, elevated CA-125, solid components, or rapid growth: warrants gynecologic oncology referral and surgical excision (usually oophorectomy given lower fertility priority and higher cancer suspicion in this group).

3. Endometriomas

Symptomatic or those affecting fertility are typically managed surgically (cystectomy). Medical therapy (GnRH agonists, danazol, progestins, aromatase inhibitors) can suppress growth/symptoms but does not eliminate the cyst - a 2024 meta-analysis found medical therapy reduces cyst size and pain but recurrence is common after stopping treatment (PMID: 37944155).
Caution: laparoscopic electrocoagulation of the cyst bed to control bleeding after endometrioma cystectomy is associated with measurable damage to ovarian reserve (lower AMH) compared with suturing - a 2024 systematic review/meta-analysis (PMID: 39145875).

4. Neonatal/fetal simple ovarian cysts

Most regress spontaneously. A 2024 European Paediatric Surgeons' Association consensus statement recommends observation for simple cysts, with intervention (aspiration or laparoscopic surgery) reserved for large (typically > 4-5 cm), symptomatic, or complex/torsed cysts to preserve ovarian tissue (PMID: 37557903).

5. Acute complications (torsion, rupture, hemorrhage)

Larger cysts (generally > 5 cm) carry higher torsion risk. Acute severe pain, peritoneal signs, or hemodynamic instability from rupture/hemorrhage requires urgent surgical evaluation, sometimes emergent laparoscopy.
Intraoperative cyst spillage (e.g., dermoid, endometrioma) during cystectomy has a well-documented but generally low risk of chemical peritonitis or local recurrence, per a 2021 systematic review/meta-analysis (PMID: 33279627); careful surgical technique to avoid spillage is still recommended.

Surgical options

Cystectomy (ovary-sparing removal of the cyst wall): preferred when fertility preservation matters and the cyst appears benign.
Oophorectomy: considered for postmenopausal women, very large cysts, or when malignancy is suspected.
Laparoscopy: first-line for most benign-appearing cysts, feasible for masses up to ~15-20 cm depending on surgeon experience and cyst characteristics.
Laparotomy: reserved for very large cysts, suspected malignancy needing full staging, or when laparoscopic removal isn't safe.

Bottom line

Size alone rarely dictates treatment in isolation - morphology (simple vs complex), symptoms, menopausal status, CA-125, and growth pattern matter as much as absolute size. A reasonable rule of thumb: simple cysts under 5 cm are usually observed, 5-10 cm warrant closer surveillance or consideration of surgery depending on symptoms/persistence, and anything over 10 cm or with complex/solid features generally merits surgical evaluation.

No recent meta-analyses or guidelines were found that contradict these thresholds; the 2023 postmenopausal cyst meta-analysis (PMID: 36787526) and the 2024 neonatal consensus statement (PMID: 37557903) both reinforce a trend toward more conservative management of simple cysts across age groups when malignancy risk is low.# 35 mm Unilateral Adrenal Mass (Adrenal Incidentaloma)

A 3.5 cm unilateral adrenal mass falls just under the most widely used "high-risk" size cutoff of 4 cm, so size alone does not mandate surgery here - but a full functional and imaging work-up is still required before deciding on observation vs. resection.

Step 1: Is it functional? (biochemical work-up - do this regardless of size)

Per Current Surgical Therapy and the 2023 European Society of Endocrinology (ESE) guideline (PMID: 37318239), every incidentaloma needs:

1 mg overnight dexamethasone suppression test (cortisol > 1.8 µg/dL [>50 nmol/L] suggests autonomous cortisol secretion - now termed "mild autonomous cortisol secretion," MACS)
Plasma or 24-hour urinary fractionated metanephrines (rule out pheochromocytoma)
Plasma aldosterone/renin ratio if hypertensive and/or hypokalemic (rule out primary aldosteronism)
Clinical screen for Cushingoid features, catecholamine excess symptoms (headache, palpitations, diaphoresis), and hypokalemia/refractory hypertension

If hormonally active (Cushing's, pheochromocytoma, aldosteronoma) -> surgery is indicated regardless of the 3.5 cm size.

Step 2: Malignancy risk by imaging + size

On unenhanced CT:

Homogeneous and ≤10 Hounsfield units (HU) -> classic benign adenoma appearance -> no further imaging needed, regardless of size (this is a key change in the 2023 ESE guideline)
If not clearly benign (HU >10, heterogeneous, irregular margins) -> needs further characterization (washout CT, MRI, or multidisciplinary discussion)

Size-stratified malignancy risk (adrenocortical carcinoma), from Current Surgical Therapy / Campbell-Walsh Urology:

Size	Approx. ACC risk	Typical recommendation
< 4 cm	~2-3%	Observation if benign imaging features and non-functional
4-6 cm	~6-7%	Consider adrenalectomy if surgically fit
> 6 cm	~25%	Adrenalectomy generally recommended

At 35 mm, the mass is in the low-risk (<4 cm) category for malignancy. Per the ESE/ENSAT 2023 guideline, surgery for a purely size-based indication is reserved for masses >4 cm that are also inhomogeneous or have HU >20 - a 3.5 cm lesion doesn't meet this threshold on size alone.

Step 3: Decision

Non-functional + clearly benign imaging (homogeneous, ≤10 HU): no surgery, no further imaging needed at all - this is a genuinely benign adenoma.
Non-functional + indeterminate imaging: multidisciplinary discussion; options are additional imaging (washout CT or MRI), interval follow-up imaging at 6-12 months, or (individualized) surgery. A significant interval growth (ESE: >20% and ≥5 mm; older AACE/AAES criteria: ≥0.5-1 cm) raises suspicion and favors resection.
Functional (even mild/subclinical cortisol excess with comorbidities like hypertension or type 2 diabetes): surgery should be considered on an individualized basis even without malignant features.
Suspicious features regardless of size (irregular margins, rapid growth, necrosis, calcification, local invasion): resection.

If surgery is chosen

At 35 mm, this is comfortably within the range for minimally invasive (laparoscopic) adrenalectomy - NCCN's cutoff for laparoscopic approach is up to 4 cm, while ESE/ENSAT extends it to 6 cm; open adrenalectomy is reserved for larger or overtly malignant-appearing tumors.

Bottom line for a 35 mm unilateral adrenal incidentaloma

Rule out hormone excess (cortisol, metanephrines, aldosterone/renin if hypertensive/hypokalemic).
Characterize on unenhanced CT: if homogeneous and ≤10 HU, this is a benign adenoma - no surgery, no further imaging.
If indeterminate imaging or any functionality, individualize between interval imaging (6-12 months) and laparoscopic adrenalectomy - size alone (3.5 cm) is not an automatic indication for surgery, since it's below the ~4-6 cm thresholds most guidelines use to trigger resection based on size.

Sources: Current Surgical Therapy, 14th ed. (Adrenal Incidentaloma chapter); Campbell-Walsh-Wein Urology (Adrenal Masses); the 2023 ESE/ENSAT clinical practice guideline on adrenal incidentalomas (PMID: 37318239); and the 2023 CUA/AUA-endorsed guideline on incidentally discovered adrenal masses (PMID: 37556768), which corroborates the same size/imaging-based risk stratification.I'm not sure what you mean by "Fluid Field" - could you clarify? A few possibilities:It looks like my last question didn't get answered before your next message came through, and I don't see any new content besides the budget update - could you resend what you'd like to know about "Fluid Field"? For context, are you asking about:

A fluid-filled cyst/lesion on imaging (e.g., ovarian, adrenal, or another site)
The field of view in an ultrasound or CT scan showing a fluid collection
Something else entirely (a different term or topic)

Let me know and I'll dig into it.